Pharmaceutical company Grünenthal has announced the acquisition of US-based Valinor Pharma, LLC and its product Movantik® (naloxegol), with a total deal value of approximately $250 million, inclusive of all royalty obligations. The acquisition further strengthens Grünenthal’s presence in the United States and adds to its growing portfolio of established medicines.
Movantik® is an oral treatment for opioid-induced constipation in adult patients with chronic non-cancer pain. The transaction expands Grünenthal’s portfolio and strengthens its position in the important US market. In 2023, Movantik® grossed over $200 million in sales in the United States.
Gabriel Baertschi, CEO of Grünenthal, stated, “As a pain specialist, Movantik is a perfect fit for Grünenthal with our existing customer base and complementary product portfolio. The acquisition of Valinor Pharma strengthens our footprint in the United States, the most important growth market for Grünenthal.”
Marv Kelly, President of Grünenthal US, added, “We are excited to welcome Valinor and expand our portfolio offering to pain specialists with Movantik.”
Grünenthal previously acquired the European rights to Movantik® in 2023 through a joint venture with Kyowa-Kirin. With the acquisition of Valinor, Grünenthal now holds worldwide ownership of the brand, excluding Canada.
The acquisition of Movantik® aligns with Grünenthal’s strategy of acquiring established medicines to expand its portfolio and increase profitability. Since 2017, Grünenthal has completed several successful M&A transactions, including the acquisition of NebidoTM, the European rights to CrestorTM and NexiumTM, and the global rights to VimovoTM, QutenzaTM, and ZomigTM.
Grünenthal has also invested more than €2 billion in successful M&A transactions, including the establishment of Grünenthal Meds, a joint venture with Kyowa Kirin International focused on pain management.
Headquartered in Aachen, Germany, Grünenthal has affiliates in 27 countries and products available in approximately 100 countries. In 2023, the company had 4,400 employees and achieved revenues of €1.8 billion.
For more information about Grünenthal, please visit www.grunenthal.com and refer to the Grünenthal Report 2023/24. Follow Grünenthal on LinkedIn (Grunenthal Group) and Instagram (@grunenthal).
For media inquiries, please contact Florian Dieckmann, Head of Global Corporate Affairs, at florian.dieckmann@grunenthal.com.
This news release is distributed by Pressat on behalf of Grünenthal.
